Quest Diagnostics (DGX) Valuation Rose While Ardevora Asset Management Llp Has Trimmed Position; Great Point Partners Boosted Its Ptc Therapeutics Cmn (PTCT) Position by $10.01 Million

May 18, 2018 - By Vivian Currie

Quest Diagnostics Incorporated (NYSE:DGX) Logo

Jeffrey Jay increased its stake in Ptc Therapeutics Inc. Cmn (PTCT) by 136.04% based on its latest 2017Q4 regulatory filing with the SEC. Great Point Partners Llc bought 625,800 shares as the company’s stock rose 91.83% while stock markets declined. The hedge fund run by Jeffrey Jay held 1.09 million shares of the health care company at the end of 2017Q4, valued at $18.11 million, up from 460,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc. Cmn for a number of months, seems to be bullish on the $1.46B market cap company. The stock increased 1.51% or $0.47 during the last trading session, reaching $31.54. About 585,988 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 274.65% since May 18, 2017 and is uptrending. It has outperformed by 263.10% the S&P500.

Ardevora Asset Management Llp decreased its stake in Quest Diagnostics Inc (DGX) by 7.92% based on its latest 2017Q4 regulatory filing with the SEC. Ardevora Asset Management Llp sold 30,300 shares as the company’s stock rose 0.72% while stock markets declined. The institutional investor held 352,400 shares of the medical specialities company at the end of 2017Q4, valued at $34.71M, down from 382,700 at the end of the previous reported quarter. Ardevora Asset Management Llp who had been investing in Quest Diagnostics Inc for a number of months, seems to be less bullish one the $13.81B market cap company. The stock decreased 0.09% or $0.09 during the last trading session, reaching $101.71. About 705,795 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has risen 1.33% since May 18, 2017 and is uptrending. It has underperformed by 10.22% the S&P500.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. PTC Therapeutics had 40 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Friday, October 16 by RBC Capital Markets. The rating was downgraded by RBC Capital Markets on Wednesday, February 24 to “Sector Perform”. On Wednesday, February 24 the stock rating was downgraded by Citigroup to “Neutral”. As per Thursday, September 14, the company rating was maintained by RBC Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Friday, July 31. As per Tuesday, February 23, the company rating was downgraded by JP Morgan. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Monday, November 14 by Credit Suisse. The stock has “Hold” rating by RBC Capital Markets on Monday, January 29. The company was downgraded on Monday, October 9 by JP Morgan. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, March 7 report.

Since January 3, 2018, it had 0 buys, and 4 sales for $61,523 activity. $12,675 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) was sold by Almstead Neil Gregory. $7,280 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) was sold by Utter Christine Marie on Wednesday, January 3.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.73, from 1.71 in 2017Q3. It is negative, as 23 investors sold PTCT shares while 35 reduced holdings. 23 funds opened positions while 34 raised stakes. 35.45 million shares or 7.80% more from 32.89 million shares in 2017Q3 were reported. Fisher Asset Mgmt, a Washington-based fund reported 165,658 shares. Kerrisdale Advisers Limited Liability Corp invested in 35,000 shares or 1.18% of the stock. Chicago Equity Prtnrs Limited invested 0.01% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Ameriprise Fincl, a Minnesota-based fund reported 25,996 shares. Tower Rech Capital Llc (Trc) holds 0% or 1,413 shares. Hudson Bay Cap Limited Partnership stated it has 0.02% in PTC Therapeutics, Inc. (NASDAQ:PTCT). State Street Corporation has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Blackrock Inc holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 3.09M shares. Rhumbline Advisers holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 39,196 shares. Hanseatic Mgmt Ser accumulated 83 shares. Quantbot Tech Ltd Partnership reported 1,067 shares or 0% of all its holdings. Northern holds 667,657 shares. Morgan Stanley reported 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Ontario – Canada-based Manufacturers Life Ins Com The has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Alps Inc has 45,975 shares for 0.01% of their portfolio.

Another recent and important PTC Therapeutics, Inc. (NASDAQ:PTCT) news was published by Nasdaq.com which published an article titled: “Analysis: Positioning to Benefit within Entergy, Schneider National, CH Robinson Worldwide, PTC Therapeutics, Guess …” on May 09, 2018.

Great Point Partners Llc, which manages about $935.83 million and $586.07M US Long portfolio, decreased its stake in Rigel Pharmaceuticals Inc Cmn (NASDAQ:RIGL) by 1.22M shares to 7.89M shares, valued at $30.61 million in 2017Q4, according to the filing. It also reduced its holding in Global Blood Therapeutics Inc. Cmn (Call) by 360,498 shares in the quarter, leaving it with 200,000 shares, and cut its stake in Dbv Technologies Sa Sponsored Adr Cmn.

Analysts await Quest Diagnostics Incorporated (NYSE:DGX) to report earnings on July, 24. They expect $1.72 EPS, up 10.97% or $0.17 from last year’s $1.55 per share. DGX’s profit will be $233.61M for 14.78 P/E if the $1.72 EPS becomes a reality. After $1.52 actual EPS reported by Quest Diagnostics Incorporated for the previous quarter, Wall Street now forecasts 13.16% EPS growth.

Ardevora Asset Management Llp, which manages about $3.33 billion US Long portfolio, upped its stake in Nordstrom Inc (NYSE:JWN) by 20,600 shares to 589,800 shares, valued at $27.95 million in 2017Q4, according to the filing. It also increased its holding in Carnival Corp (NYSE:CCL) by 52,700 shares in the quarter, for a total of 436,400 shares, and has risen its stake in Ferrari N V.

Since January 2, 2018, it had 0 insider buys, and 13 selling transactions for $30.90 million activity. RUSCKOWSKI STEPHEN H had sold 106,840 shares worth $11.43 million. Another trade for 21,294 shares valued at $2.21 million was made by Doherty Catherine T. on Wednesday, January 24. On Thursday, March 8 Cohen Jon R sold $8.72M worth of Quest Diagnostics Incorporated (NYSE:DGX) or 83,669 shares. 4,128 shares valued at $416,928 were sold by PREVOZNIK MICHAEL E on Friday, March 2. Klug Robert A had sold 1,157 shares worth $119,932.

More news for Quest Diagnostics Incorporated (NYSE:DGX) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on May 01, 2018. Globenewswire.com‘s article titled: “Report: Exploring Fundamental Drivers Behind Valvoline, KKR & Co., Otonomy, Radian Group, Red Rock Resorts, and …” and published on May 11, 2018 is yet another important article.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.